DDA podcast looks at private weight loss clinics
Oral orforglipron GLP1 (marketed in the USA by Lilly as Foundayo) was authorised for use in weight management and type 2 diabetes in August 2026, in a UK first.
In this new DDA podcast, the 12th in our series, DDA Communications Officer Ailsa Colquh
September 15th 2026